Volasertib

Orally active, ATP-competitive, potent and selective polo-like kinase (PLK) inhibitor with anti-cancer efficacy in cultures and in vivo.

Volasertib (BI 6727) is an orally active, ATP-competitive, potent and selective polo-like kinase (PLK) inhibitor (PLK1/2/3 IC50 = 0.87/5/56 nM by kinase assay with 7.5 μM ATP) with no significant inhibitory potency (at 10 μM) toward a panel of >50 other kinases. Volasertib exhibits antiproliferation efficacy in cancer cultures (IC50 from 11 to 37 nM) and in mice in vivo via i.v. (20-30 mg/kg/wk or 10-25 mg/kg 2x a wk; HCT-116 & CXB1 xenografts) or p.o. (7-10 mg/kg/d, 15-25 mg/kg 2x a wk, 50-70 mg/kg/wk; NCI-H460, HCT-116 & CXB1 xenografts).